The Law Offices of Frank R. Cruz announces an investigation of Dr. Reddy’s Laboratories (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) on behalf of investors concerning the Company’s possible violations of federal securities laws.

On July 22, 2026, Dr. Reddy’s announced its first quarter fiscal 2027 earnings, reporting, among other things, earnings per share of only $0.06, due in part to the adverse impact of a ₹2.4 billion provision related to out-of-specification semaglutide batches. CEO Erez Israeli said “The quarter’s EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs.”

On this news, the price of Dr. Reddy’s Laboratories stock price fell $1.18, or 9.4%, to close at $11.38 on July 22, 2026, thereby injuring investors.